Trial Profile
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Clear cell sarcoma; Endometrial cancer; Sarcoma; Squamous cell cancer
- Focus Therapeutic Use
- 27 Mar 2024 Planned End Date changed from 14 Mar 2024 to 26 Mar 2025.
- 27 Mar 2024 Planned End Date changed from 14 Mar 2024 to 26 Mar 2025.
- 28 Mar 2023 Planned End Date changed from 14 Mar 2023 to 14 Mar 2024.